Investec raise to buy today |
As I gather the regular posters on this board are in for the long haul (or have already been hauling for a very long time!) we all might benefit from an increased knowledge of the industry. McKinsey have an industry briefing on Cell & Gene Therapy, and while I've not yet read through the articles myself (I will do at the weekend) here is the link. https://www.mckinsey.com/industries/life-sciences/our-insights/mckinsey-insights-on-cell-and-gene-therapy |
End of another chapter in OXB`s history.
AstraZeneca is withdrawing its Covid-19 vaccine worldwide |
That was one oral presentation of the two OXB are presenting at ASGCT24 this week.
They also have 9 posters accepted. 1 about further developing TRiP and 8 others. |
AAV Manufacturing Takes Centre Stage at ASGCT24
Published: May 07, 2024
Oxford Biomedica’s Alex Meola also discussed the use of additives to help isolate the full capsids from not only empty capsids but from a third group that includes a mixture of empty and DNA-containing capsids. “Not all empty capsids are created equal,” he noted, but the company’s proprietary additive combined with the use of anion-exchange chromatography (AEX), which uses AAVs’ positive charge to separate the vectors from impurities during production, was able to increase yield. |
Going to be another million share day in a few minutes.
I preferred this morning at 4% up to this afternoon at 4% down. |
John Evans
@john_evans3
·
2h
We believe BEAM-101 can become the best-in-class editing option for patients with severe SCD, with first data later this year.
John Evans
@john_evans3
·
1h
We are also on track starting up the BEAM-302 trial in the UK for AATD after clearance by the MHRA, and the BEAM-301 US IND is coming soon as well.
Thank you to the team and all our patients and investigators. Lots of progress ahead for base editing in the clinic! |
Well,well......there's the anticipated tree shake.The MMs know after last week that there's no shortage of short term profits that private clients might be tempted to bank.The next couple of hours will confirm whether there's some ongoing US interest and whether we'll establish a meaningful base camp for a further climb. |
The ebullience of the post Q&A session does suggest that there could be numerous favourable developments in the offing and one might well be inhibiting insider buying.I agree with Chillpill that the collapse in the share price was something of an aberration due to redemption selling.There seemed no reason for the price to tumble some 40% post the RNS outlining the ABL/I.M.agreement.The price is now getting back on track to where one might of expected it to be in the days/weeks post the Institut Merieux deal.I still feel,after some understandable churning around this level that we should move towards that agreed magic price of 407.4p.It would be nice if we could rationalise every stock move but sometimes the market's just plain daft simply reflecting buying and selling |
Update on the YTB323 trial (Novartis T-Charge) for which we supply the vector.
As of 2nd May now recruiting 225 patients at 39 sites worldwide.
That's big for a CAR-T trial and just for the lead YTB323 trial. They have 2 others following on.
The big advantage of T-Charge is that it's just over a week to treat a patient, whereas current CAR-T is about 3 weeks. That reduction in waiting time makes a big difference for very poorly patients who have failed on other medicine and putting it into them earlier also helps with the storm response. |
But if it is that, then it's not a good explanation for no insiders buying - is it? |
The other possibility here relates to the last question in the Q&A at the end of the webcast, which was about what happens if the US government puts sanctions on China for CDMO - and in particular WuXi?
I read this morning that the senate committee voted 11-1 to take that to the next stage.
That won't be quick as both the senate and the house have to vote on it. If both vote yes then they need to wake the president up and put a pen in his hand.
However, if you were looking to place a CDMO deal now, then it's something you would think about isn't it?
Similarly if you are already locked into China then will you be looking for a contingency plan involving another supplier?
Isn't this the type of thing which hedge funds make their money taking positions on? |
I see the price fall below £4 as an aberration as there were forced institutional sellers on the back of falling out of the FTSE and MSCI indices.
BioMerieux and Novo Nordisk have picked up a lot of that stock and won’t be selling any time soon. |
Two large trades have paid a significant premium so we have some impatient buyers.
If sellers think (correctly) that we are on a roll and decide to hold off (most of the really urgent ones may well be out by now - or at least soon) then we could have a very tight market and the makings of a spike. So far it has been active but orderly with more sellers being coaxed out for a few extra pence.
[Ed]....and a significant spike would start the rumour mill grinding. |
Very curious isn't it?
We expected / hoped for post results press coverage over the weekend - and there was none (so it isn't that).
If it's the people who follow / would normally be interested in OXB who are buying, then surely they would have seen the '23 firm guidance and '24 forecast before results day. Why are they suddenly buying strongly at day 6?
Why have none of the insiders bought?
It does all suggest that there is something else expected. |
£65k buy |
Post results presentations seem to have gone well! |
If you click "download" on this, it will give you an excel sheet with the day's trades so far |
(which have gone now) |
Not showing on anything I can see phil.
On the secret order depth page
(click "today" and scroll to the bottom of the page)
There are a line of 5,000 sized trades on both sides though. |
Is that 2m bought this morning? |
Another strong start to the week. Long may it continue. |
www.independent.co.ug/who-africa-has-made-remarkable-vaccination-progress-more-can-be-done/
"The other vaccine discovered in 2023 is R21/Matrix M.
Jaishree Raman, of the Malaria Operational Research at the National Institute for Communicable Diseases in South Africa, explains that the “R21 vaccine is a significant improvement on the RTS, S vaccine, with 75% efficacy over a year.” The R21 vaccine is also cheaper.
After Cabo Verde achieved a significant milestone by securing malaria-free certification in January, more countries are ramping up vaccination efforts, leveraging the new vaccines on the market.
In the past week, Liberia, Benin and Sierra Leone have become the latest countries to roll out large-scale vaccination drives targeting millions of children.
According to the WHO, the addition of the three brings to 8 the number of countries on the continent that offer a malaria vaccine as part of their childhood immunization programmes." |
The notes I've seen in the past usually have an escape clause written in. So they give you a target price and then a spread of an upside and downside case.
If it's working out either way then they have a route to the next note where they remind you of (in this case) the upside case, then rerate on the next useful piece of news.
As mentioned earlier it will be interesting to see how the four days of this week work out. If it continues to climb then great, if not then it might need help with some news.
We might find out that a lot of the brokers are quite reluctant to do a full 180 until the interims when Stuart tells us the H1 results and gives his 85% forecast for the full year.
Big news with a name which everybody recognises would probably help convince quite a few people in the nearer term. |
What does Stifel say now then with a buy up to 300 and we are well above this - do they move to hold I guess - I think one other broker had a target of 250 but the others on post 7682 are higher so no impact for now I suspect.... |
Register for real-time alerts, custom portfolio, and market movers
Hot Features
Premium
